Harbour Biomed Announces the Latest Clinical Data on the First-in-Class Fully Human Anti-B7h7/Hhla2 Monoclonal Antibody Hbm1020 at the Esmo Congress 2024

THOMSON REUTERS
14 Sep 2024

Harbour Biomed Announces the Latest Clinical Data on the First-in-Class Fully Human Anti-B7h7/Hhla2 Monoclonal Antibody Hbm1020 at the Esmo Congress 2024

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10